Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25094778 | 0.94 | TSHR (0.39) | TSHRKDM4EALDH1A1ALOX15OPRM1 | |
| SCHEMBL21214477 | 0.90 | L3MBTL1 (0.36) | TSHRKDM4EALDH1A1OPRM1OPRL1 | |
| SCHEMBL22921130 | 0.90 | L3MBTL3 (0.38) | TSHR | |
| SCHEMBL21214478 | 0.86 | KDM4E (0.45) | TSHRKDM4EALDH1A1ALOX15OPRM1 | |
| SCHEMBL19226645 | 0.86 | TSHR (0.43) | TSHRSIGMAR1KMT2APOLB | |
| SCHEMBL21291301 | 0.85 | L3MBTL3 (0.39) | KDM4EALDH1A1OPRL1 | |
| SCHEMBL14400051 | 0.84 | TSHR (0.38) | TSHRALDH1A1SIGMAR1KMT2A | |
| SCHEMBL11919256 | 0.82 | CHRM1 (0.40) | KDM4EALDH1A1ALOX15SIGMAR1POLB | |
| SCHEMBL21709573 | 0.81 | TSHR (0.38) | TSHRSIGMAR1POLB | |
| SCHEMBL21214511 | 0.78 | KDM4E (0.43) | KDM4EALDH1A1SIGMAR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439237-B2 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-21 | — | — | US | disclosed |
| US-20070238715-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238715-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | TSHR 437/4885KDM4E 4698/4885ALDH1A1 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.